Immunovant Historical Financial Ratios

IMVT -  USA Stock  

USD 8.30  0.17  2.01%

Immunovant is lately reporting on over 54 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Debt to Equity Ratio of 0.0554 or Price to Book Value of 4.92 will help investors to properly organize and evaluate Immunovant financial condition quickly. Financial Statement Analysis is infinitely more than just reviewing and investigating Immunovant recent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunovant is a good buy for the upcoming year.
Please see Risk vs Return Analysis.

Immunovant Historical Statements 

 
Refresh

About Immunovant Financial Ratios Analysis

ImmunovantFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunovant investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunovant financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunovant history.

Immunovant Financial Ratios Chart

Immunovant financial ratios usually calculated using numerical values taken directly from Immunovant financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Immunovant. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.

Current Ratio

The ratio between Current Assets and Current Liabilities; for companies that operate a classified balance sheet.

Return on Average Assets

Return on assets measures how profitable a company is Net Income Common Stock relative to its total assets [AssetsAvg].

Return on Average Equity

Return on equity measures a corporation's profitability by calculating the amount of Net Income Common Stock returned as a percentage of [EquityAvg].
Most ratios from Immunovant fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.
 2010 2019 2020 2021 (projected)
Current Ratio1.947.1221.7917.42
Book Value per Share0.332.184.463.69

Immunovant fundamentals Correlations

Immunovant Account Relationship Matchups

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunovant without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunovant using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Immunovant's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunovant. If investors know Immunovant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.